Objective To evaluate the association of perihemorrhagic edema (PHE) evolution and peak edema extent with day 90 functional outcome in patients with intracerebral hemorrhage (ICH) and identify pathophysiologic factors influencing edema evolution.
In intracerebral hemorrhage (ICH), there are many detrimental processes and secondary damage cascades, including inflammation and degradation of heme products, initiated immediately after ICH onset. They are hypothesized to contribute to the development of perihemorrhagic edema (PHE), which is suggested to serve as a radiologic marker for secondary injury following ICH. [1] [2] [3] [4] PHE volume may evolve within a period of 8-12 days after ictus and may exceed the initial lesion volume by more than 150%, 3 possibly causing clinical deterioration or even herniation. 5 Thus, PHE evolution and notably peak PHE volume may represent important outcome measures and treatment targets not only in the (hyper-)acute phase of ICH while established prognostic outcome measures (e.g., initial hematoma volume or age 1 ) are rather inaccessible to a treatment or show limited treatment options. 1, [6] [7] [8] Specifically, several research groups reported on an association of early PHE evolution up to 24-72 hours after ICH onset with functional outcome. [9] [10] [11] [12] However, as PHE volume may peak 8-12 days after onset, analyzing PHE evolution merely up to 72 hours after onset may yield limited results. In the present study, we correlated peak PHE volume with long-term outcome in ICH patients. Furthermore, we assessed factors associated with increased PHE evolution.
Methods

Patients
Our study retrospectively included patients with spontaneous supratentorial ICH who were admitted between January 2006 and January 2014 from our prospectively organized institutional database. We defined ICH as spontaneous if exclusively related to hypertension or amyloid angiopathy. Patients with secondary ICH were excluded. Inclusion criteria were at least 2 consecutive CT scans over a period of at least 72 hours, no withdrawal of care within 24 hours after admission, an available modified Rankin Scale score (mRS) on day 90, and a baseline mRS of <4. Furthermore, we excluded patients with surgical hematoma evacuation.
Standard protocol approvals, registrations, and patient consents The study was approved by our institutional ethics committee.
Clinical data
We obtained age, 1 mRS before symptom onset, NIH Stroke Scale score (NIHSS) on admission, 1 and other outcome predicting measures in ICH such as fever burden (defined as number of days with peak temperature ≥38°C) up to day 12 13 and serum inflammatory measures 14 including lymphocytes, neutrophils, and neutrophil to lymphocyte ratio (NLR; neutrophil count divided by lymphocyte count) on admission and days 4 and 6 as a marker for systemic inflammation also relevant for cardiovascular outcomes 15 and elevated intracranial pressure (ICP) burden (number of episodes with ICP >20 mm Hg lasting more than 5 minutes or with patients presenting with symptoms related to elevated ICP [deterioration of consciousness, anisocoria]) up to day 12 from medical records. We used standardized mailed questionnaires for the assessment of functional status before symptom onset and comorbidities if those data were not obtained during hospital stay. Time between symptom onset and admission was assessed as an important predictor of hematoma expansion. 16 The day of admission was defined as day 1.
Neuroimaging and volumetric assessment of PHE and ICH A fourth-generation CT scanner (Somatom 64 or Somatom AS+, Siemens Healthcare, Erlangen) was used for CT scans. Each scan consisted of either a multislice spiral CT dataset, 10-12 slices of 4.8 mm thickness for the skull base and 10-12 slices of 7.2 mm thickness for the cerebrum (Somatom 64), or 22-25 slices of 4.8 mm thickness for the entire brain (Somatom AS+) using the orbitomeatal plane. We used a validated semiautomatic volumetric algorithm as previously described 17 for assessment of ICH and PHE volume. For better comparison, we merged different time points of CT scans to time clusters (days 1, 2-3, 4-6, 7-9, 10-12). Initial PHE growth from baseline to 72 hours [9] [10] [11] [12] 18 (defined as absolute difference between PHE volume [mL] on day 2-3 and admission), intraventricular hemorrhage (IVH), and hematoma volume on admission 19 as well as peak PHE volume and secondary hematoma enlargement (hematoma expansion) volume were recorded. Peak PHE volume was defined as the maximum volume measured in any of the available CT scans. In the context of accuracy of measurements, 20,21 a hematoma volume increase ≥ 5 mL between 2 CT scans was defined as hematoma expansion. 7 
Outcome
We assessed functional outcome on day 90 using the mRS either by mailed standardized questionnaires or phone interviews (performed by trained and certified physicians) with patients or their next of kin if the questionnaire was not returned within 4 weeks. 22 In cases of insufficient data retrieval, we contacted primary care physicians. As primary outcome variable, mRS was dichotomized as favorable outcome (mRS 0-3) or poor outcome (mRS 4-6). As secondary Glossary CI = confidence interval; ICH = intracerebral hemorrhage; ICP = intracranial pressure; IQR = interquartile range; IVH = intraventricular hemorrhage; mRS = modified Rankin Scale; NIHSS = NIH Stroke Scale; NLR = neutrophil to lymphocyte ratio; PHE = perihemorrhagic edema; PSM = propensity score-matched; OR = odds ratio; ROC = receiver operating characteristic.
outcome measures, we analyzed the correlation of clinical characteristics and inflammatory measures with peak PHE volume and early PHE growth from baseline up to day 3 (72 hours). Patients were dichotomized according to median peak PHE volumes and median early PHE increase volumes.
Statistics
We performed statistical analyses using the IBM SPSS Statistics 21 software package (IBM Corporation, Armonk, NY) and R 2.12.0 (r-project.org). The significance level was set at α = 0.05 and statistical tests were 2-sided. Missing data regarding basic characteristics, neuroimaging, or outcome led to exclusion of patients. We used the Kolmogorov-Smirnov test to evaluate the distribution of data. Data were presented as mean ± SD (statistical test: Student t test), or as median and interquartile range (IQR, statistical test: Mann-Whitney U test), as appropriate. We used Pearson χ 2 or Fisher exact test to compare frequency distributions of categorized variables between dichotomized patient groups: (1) mRS 0-3 and 4-6, (2) patients with peak PHE volume smaller and larger than the median peak PHE volume, and (3) patients with an early PHE increase smaller and larger than the median increase of the included cohort (median split). For both groups 2 and 3, we performed a separate additional propensity score matching using the entire cohort (n = 292) based on logistic regression as estimation algorithm (nearest neighbor matching, ratio 1:1, caliper = 0.1) accounting for age, hematoma volume, and hematoma location (basal ganglia vs lobar) and calculated abovementioned univariate testing as well as additional logistic regression. To identify measures independently associated with outcome and peak PHE volume, we calculated stepwise backward inclusion multivariate logistic regression models including clinically meaningful measures showing a statistical trend (p < 0.1) in univariate testing of the entire cohort. As hematoma location (lobar vs basal ganglia) was demonstrated previously to represent an important outcome associated factor 23 with a suggested interaction with hematoma volume, 24 we also included the interaction term of both factors in our multivariate logistic regression model. Because not all patients had regular CT scans up to day 10-12 based on inclusion criteria, we performed an additional sensitivity analysis including only patients with at least 4 CT scans up to day 9. To explore associations of PHE evolution with outcome, we additionally performed receiver operating characteristic (ROC) curve analyses.
Results
Cohort
A total of 875 patients were screened. We excluded 154 patients who received early withdrawal of care, 53 patients because of surgery (hematoma evacuation) prior to control scan, and 140 patients who had only 1 CT scan. A further 38 patients were excluded due to insufficient datasets, 143 due to infratentorial hemorrhage, and 55 due to a mRS prior to the current ICH of >3. This led to 292 patients (161 male [55%]) who met inclusion criteria. A total of 121 (41%) patients presented with lobar hemorrhage and 171 (59%) with basal ganglia hemorrhage. A total of 159 patients (54%) showed an additional IVH. Median age was 70 years (IQR 62-78), median ICH volume on admission 17.7 mL (IQR 7.9-40.2), and median peak ICH volume 22.5 mL (IQR 8.9-46.4). Median PHE volume on admission was 16.3 mL (IQR 9.1-29.2) and increased to a median peak PHE volume of 37.5 mL (IQR 19.0-60.6) over a median period of 7 days (IQR 3-12). Median NIHSS on admission was 13 (IQR 6-21), median mRS on day 90 was 4 (IQR 3 to 5). Time between symptom onset and admission did not differ between patients with and without hematoma expansion up to day 3 (4.2 hours [IQR 2.1-9.0] and 5.0 hours [IQR 2.5-11.9], respectively, p = 0.234). 25 Peak PHE volume also remained the only independent outcome predictor in our sensitivity analysis including only patients with at least 4 CT scans up to day 9 (n = 218) with a comparable OR (OR 0.985 [95% confidence interval (CI) 0.973-0.997], p = 0.012) besides and adjusted for the abovementioned factors. Figure 1 illustrates PHE evolution in patients with favorable and poor outcome: patients with poor outcome showed an immense PHE increase during the first 72 hours after ICH onset compared to patients with a favorable outcome, and PHE increase continued to be less pronounced up to day 10-12.
Factors influencing outcome in ICH patients
Receiver operating characteristic analysis ROC analysis (figure e-1, links.lww.com/WNL/A258) confirmed a good predictive value of peak PHE regarding favorable outcome, especially compared to the predictive value of initial ICH volume and the well-established ICH score. 25 A cutoff value of 26.8 mL peak PHE volume was identified with a sensitivity of 0.54 and a specificity of 0.78 (Youden Index 0.326) to distinguish best between patients with a favorable and a poor outcome.
Measures influencing peak PHE volume
Given that peak PHE extent was identified as an independent predictor of long-term outcome, we studied factors influencing peak PHE volume. As demonstrated in table 3, in univariate analyses various measures including younger age, location of hematoma, IVH, hematoma volume, initial PHE increase up to day 3, fever burden, and reduced lymphocyte count on day 4-6 as well as increased NLR on day 6 were associated with an increased peak PHE volume >37.495 mL (median of the entire cohort). In multivariable testing, initial PHE increase up to day 3 and reduced lymphocytes on day 4 remained independent predictors of an increased peak PHE besides a younger age and a higher ICH volume (table 4) .
In a propensity score-matched (PSM) subgroup analysis (n = 124) accounting for ICH volume, age, and hematoma location, early PHE increase up to day 3 (OR 1.060 [95% CI 1.018-1.103]) and increased NLR on day 6 (OR 1.236 [95% CI 1.034-1.477]) were associated with an increased peak PHE (see also table e-2, links.lww.com/WNL/A259).
Measures associated with early PHE increase up to day 3 A higher early PHE increase (PSM cohort, n = 224) was significantly associated with a higher fever burden up to day 3 (OR 
Discussion
This study suggests that peak PHE volume is an independent predictor of day 90 outcome in ICH patients and is associated with age, hematoma volume, initial PHE increase up to day 3, and inflammatory measures. Each milliliter of additional peak PHE volume increased the absolute risk for a poor outcome by 1.5%. In turn, initial PHE increase was related to hematoma expansion and fever burden. These results may help to direct further research in order to shed light into the pathophysiologic mechanisms that act beyond perihemorrhagic edema evolution After ICH ictus, many inflammatory processes are initiated.
1,2
Animal studies have revealed a rise of proinflammatory mediators within hours after cerebral injury suggesting a hyperinflammatory state in the initial stages of acute brain injury 26 associated with the development of brain edema. 27 Rare human data also suggested an association of edema evolution with inflammatory measures (e.g., NLR, 28 certain interleukins, 29 or matrix metalloproteinase-9 concentrations 30 ). Furthermore, the influence of immunomodulating therapies on PHE evolution also supports this association. 31, 32 Those inflammatory processes start within hours after ICH onset and continue up to several days. 1 This underlines their importance regarding PHE evolution both in the acute phase and in the postacute period when PHE volume continues to increase. 3 This link between PHE evolution and inflammatory measures as well as the role of PHE as an imaging marker of inflammatory processes in ICH patients is further strengthened and confirmed in light of the findings of our study. It also supports an independent prognostic effect of peak PHE volume on outcome.
Previous reports found a strong correlation between PHE volume and outcome in ICH patients when analyzing PHE evolution up to 72 hours after onset. Wu and colleagues 12 reported that the early edema extension distance increase up to 72 hours after onset independently influenced mortality after ICH. An analysis by Venkatasubramanian and colleagues 33 including 27 patients found a correlation of PHE Figure 1 Evolution of absolute hematoma and perihemorrhagic edema (PHE) volume up to day 10-12 in patients with favorable and poor outcome
Only patients with ≥5 CT scans up to day 10-12 (n = 170) were included. Blue lines represent favorable outcomes, red lines poor outcomes, dotted lines hematoma volumes, and continuous lines perihemorrhagic edema (PHE) volumes. Patients with poor outcome showed not only a higher PHE volume increase during the first 72 hours after onset compared to patients with favorable outcome, but also to a lesser extent up to day 10-12. volume growth up to 48 hours with clinical status at 48 hours while there was no association of total PHE volume growth with 3-month functional outcome. A pooled analysis of the INTERACT data showed that early PHE increase up to 24 hours after onset is an independent predictor of death and dependency on day 90 after ICH. 9 Similar results could also be shown by Urday et al. 11 and Murthy et al., 34 leading to consistent results observed in about 3,000 patients. Our data revealed an unadjusted association of early PHE increase with outcome. Furthermore, as we included PHE data of a wide temporal range, our data suggest that it is primarily the peak PHE volume that matters regarding outcome measures. On the other hand, our analysis also demonstrated an independent correlation of early PHE increase with peak PHE volume. Thus, early PHE increase may serve as a predictor of peak PHE volume. The latter was independently associated with poor outcome in our cohort.
Several therapeutic options targeting the abovementioned mechanisms may evolve. At first sight, removing the blood clot might be the most pragmatic approach. However, so far a general superiority of surgical intervention in ICH patients as compared to conservative treatment could not be shown. 35 A minimally invasive approach is currently tested in the MISTIE trial, so far yielding promising results concerning PHE reduction in the phase II trial, 36 however, with an increased rate of asymptomatic bleeding in patients treated with minimally invasive surgery plus alteplase for clot removal. 7 Hematoma expansion could be limited by administration of a hemostatic therapy with rFVIIa, however, with no improvement in survival or functional outcome. PHE evolution was not analyzed in this trial. 8 Another approach targeting multiple pathophysiologic pathways associated with PHE evolution is therapeutic hypothermia. 26 Therapeutic hypothermia effectively reduced PHE volume, 32 especially when initiated early after ICH onset. 37 These findings underline the importance of early inflammatory processes regarding PHE evolution, as suggested in our study. However, the question how long to treat and which target temperature to obtain to improve outcome needs to be elucidated in future research. A third possible treatment target is inflammation. Only a few studies with small patient numbers analyzed the effect of corticosteroids in ICH patients and found no effect on mortality and infections. 38 Thus, European Stroke Organisation guidelines do not recommend the use of corticosteroids at this time. 39 Other anti-inflammatory substances, e. g., fingolimod, are under clinical investigation. 31 However, it remains to be elucidated whether the inflammatory response related to PHE evolution represents rather a reaction to the occurrence of blood within brain parenchyma, a reaction to additional infectious diseases in severely ill patients, or both, and whether an immunosuppressive strategy, an antiinfectious strategy, or both will resolve the inflammatory dilemma in ICH patients.
There are several strengths of the present study: we could include a sound cohort of an adequate size with available longterm data regarding PHE evolution and outcome assessment. Furthermore, a validated measurement was used for quantification of PHE and ICH volume, 17 yielding reliable and robust results.
There are also several limitations. Despite the proper size of the included cohort, only patients from a single center were included. Due to the retrospective design, there were no standardized time points of imaging. To obtain comparable results, we merged imaging data within prespecified time clusters. This procedure might lead to an underestimation of peak PHE volume and also to a distorted representation of early PHE volume increase up to day 3 and the time axis of PHE evolution. However, this bias exists for all outcome groups. Due to the exclusive inclusion of supratentorial ICH patients, no statement about the association of PHE with functional outcome in infratentorial ICH patients is yet possible. A further selection bias also cannot be excluded as we did not include patients with early withdrawal of care and patients with only 1 CT scan (n = 294) and excluded 38 patients due to missing data. Because length of hospital stay and number of CT scans varied between individuals, in some patients the real peak PHE volume might not have been assessed. We used the method of median split to assess measures influencing peak PHE volume leading to a possible loss of power in this analysis. Validation of our methodology was performed up to day 5 after admission. We cannot exclude that due to ongoing hematoma degradation a certain inaccuracy may affect our PHE assessment between day 6 and 12, even if our method corrects for hematoma degradation.
Time between symptom onset and admission did not differ between patients with and without hematoma expansion. However, as this measure differed between individual patients, it might pose possible bias in this complex relation among hematoma evolution, PHE evolution, outcome, and time.
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